Protocol title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparatorcontrolled Study Evaluating the Efficacy and Safety of Guselkumab for the Treatment of Subjects with Moderate to Severe Plaque-type Psoriasis
Registry: ClinicalTrials.gov
Registry #: NCT02207231
Link to registry: See Registry
Protocol title: A Phase 2b, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-154 Foam 0.3% Administered QD in Adolescents and Adults With Scalp and Body Psoriasis
Registry: ClinicalTrials.gov
Registry #: NCT04128007
Link to registry: See Registry
Protocol title: A phase 2b, double-blind, randomised, 5-arm, vehicle-controlled, dose-ranging trial to evaluate the efficacy and safety of twice daily topical applications of delgocitinib cream 1, 3, 8, 20 mg/g for 8 weeks in adult subjects with mild to severe atopic dermatitis
Registry: ClinicalTrials.gov
Registry #: NCT03725722
Link to registry: See Registry
Protocol title: A randomised, double-blind, placebo-controlled, parallel-group, multi-centre trial to evaluate the efficacy, safety, and tolerability of tralokinumab monotherapy in adolescent subjects with moderate-to-severe atopic dermatitis who are candidates for systemic therapy.
Registry: ClinicalTrials.gov
Registry #: NCT03526861
Link to registry: See Registry
Protocol title: A Phase 3b Multicenter, Randomized, Double-Blind, Double-Dummy, Active Controlled Study Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Adult Subjects with Moderate to Severe Atopic Dermatitis
Registry: ClinicalTrials.gov
Registry #: NCT03738397
Link to registry: See Registry
Protocol title: A Phase 2b Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 With A Partially Blinded Extension Period To Evaluate The Efficacy And Safety Of Pf-06651600 And Pf-06700841 In Subjects With Active Non-segmental Vitiligo
Registry: ClinicalTrials.gov
Registry #: NCT03715829
Link to registry: See Registry
Protocol title: A Phase 3 Multi-center, Long-term Extension Study Investigating the Efficacy and Safety of Abrocitinib, With or Without Topical Medications, Administered to Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
Registry: ClinicalTrials.gov
Registry #: NCT03422822
Link to registry: See Registry
Protocol title: A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients with Severe or Very Severe Alopecia Areata
Registry: ClinicalTrials.gov
Registry #: NCT03899259
Link to registry: See Registry
Protocol title: A Phase 3 Multicenter, Double-Blind Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Adult Patients with Atopic Dermatitis
Registry: ClinicalTrials.gov
Registry #: NCT03334435
Link to registry: See Registry
